Predictive Oncology (POAI) Expected to Announce Earnings on Wednesday

Predictive Oncology (NASDAQ:POAI) is expected to announce its Q4 2025 results after the market closes on Wednesday, April 8th. Analysts expect Predictive Oncology to post earnings of $0.90 per share and revenue of $5.00 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, April 1, 2026 at 8:30 AM ET.

Predictive Oncology Stock Down 5.2%

NASDAQ:POAI opened at $1.47 on Wednesday. Predictive Oncology has a 52-week low of $3.88 and a 52-week high of $45.90. The stock has a fifty day simple moving average of $2.50 and a 200-day simple moving average of $6.57. The company has a market capitalization of $4.99 million, a PE ratio of -0.11 and a beta of 1.35.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded shares of Predictive Oncology to a “strong sell” rating in a report on Saturday, December 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Predictive Oncology presently has a consensus rating of “Sell”.

About Predictive Oncology

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.